News

The company said it plans the commercial launch of the Vision-MR Ablation Catheter and the new AdvantageMR system in June across new and existing sites in Europe.

Telix Pharmaceuticals (ASX:TLX) has announced that preliminary results from the Phase 2 IPAX-Linz study of TLX101 in recurrent high-grade glioma support the patient benefit seen in the IPAX-1 study.

Clinical stage oncology company Prescient Therapeutics (ASX:PTX) has announced the US FDA has granted PTX-100 a Fast Track Designation for the treatment of adults with relapsed or refractory mycosis fungoides, the most common subtype of Cutaneous T Cell Lymphoma.

Cell therapy company Cartherics has announced the appointment of Professor Bryan Williams as its new board chair and Laurence Nore as a non-executive director.

Researchers at the University of Queensland are attempting to create a vaccine in just 150 days to demonstrate their ability to respond to a pandemic as part of a program backed by the Coalition for Epidemic Preparedness Innovations.

Argent BioPharma (ASX:RGT) and AusCann have signed a strategic heads-of-agreement to advance cannabinoid-based pharmaceutical development.

Botanix Pharmaceuticals (ASX:BOT) has received commitments from a significant number of new leading Australian and international institutional investors, alongside key existing institutional and sophisticated investors, to raise $40 million.

Cell therapy immuno-oncology company Carina Biotech has reported a successful $5 million capital raise from existing and new shareholders.

Noxopharm (ASX:NOX) has announced that its SOF-SKN lupus medication has passed its final in vivo preclinical safety study before regulatory submission for the upcoming HERACLES clinical trial.

Neuren Pharmaceuticals (ASX:NEU) has announced that the primary endpoints for its planned single Phase 3 pivotal clinical trial of NNZ-2591 in Phelan-McDermid syndrome have been confirmed at a Type C Meeting with the US FDA.

Recce Pharmaceuticals (ASX:RCE) has announced a significant capital raise to support Phase 3 topical clinical trials in Indonesia and Australia.

Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) has announced the appointment of Melanie Farris to the board as an independent non-executive director.